Kringle domain 1 of human hepatocyte growth factor and uses therefor
OwnerLi Xin, Zai-Ping Li +3inventors
InventorsLi Xin, Zai-Ping Li, Ren-Bao Gan, Qing-Wei Zhou, Ren Xu
Life of this patent
Estimating the term…
Abstract
This invention relates generally to the field of growth factor. In particular, the invention provides an isolated nucleic acid fragment, comprising a sequence of nucleotides encoding a Kringle domain 1 of human hepatocyte growth factor (HGFK1). Proteins or peptides encoded by the HGFK1 nucleic acids are also provided. Compositions comprising HGFK1 nucleic acids, proteins, or functional derivatives or fragments are also provided. Methods for producing and/or using HGFK1 nucleic acids, proteins, or functional derivatives or fragments are further provided.
Claims34
An isolated nucleic acid fragment, comprising a sequence of nucleotides encoding a Kringle domain 1 of human hepatocyte growth factor (HGFK1).
A substantially purified HGFK1.
A conjugate, comprising:
- a) a HGFK1;
- and
- b) a facilitating agent linked to the HGFK1 directly or via a linker, wherein the agent facilitates:
- i) affinity isolation or purification of the conjugate;
- ii) attachment of the conjugate to a surface;
- or
- iii) detection of the conjugate.
A method for inhibiting pathological cell growth or angiogenesis, which method comprises administering to a subject to which such inhibition is needed or desirable, an effective amount of HGFK1, or a functional derivative or fragment thereof, or a nucleic acid encoding said HGFK1 or functional derivative or fragment thereof, or an agent that increases production and/or cell growth or angiogenesis inhibiting function of said HGFK1, thereby inhibiting said pathological cell growth or angiogenesis in said subject.
A pharmaceutical composition for inhibiting pathological cell growth or angiogenesis, which pharmaceutical composition comprises an effective amount of HGFK1, or a functional derivative or fragment thereof, or a nucleic acid encoding said HGFK1 or functional derivative or fragment thereof.
A combination for inhibiting pathological cell growth or angiogenesis, which combination comprises:
- a) an effective amount of an agent that inhibits pathological cell growth or angiogenesis;
- and
- b) an effective amount of HGFK1, or a functional derivative or fragment thereof, or a nucleic acid encoding said HGFK1 or functional derivative or fragment thereof, or an agent that increases production and/or cell growth or angiogenesis inhibiting function of said HGFK1, thereby inhibiting said pathological cell growth or angiogenesis in said subject.
Dependencies are inferred from the claim text.